

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

United States Patent and Trademark
Office
(Box PCT)
Crystal Plaza 2
Washington, DC 20231
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 19 June 1998 (19.06.98)	
International application No. PCT/JP97/04193	Applicant's or agent's file reference PWO-16397
International filing date (day/month/year) 18 November 1997 (18.11.97)	Priority date (day/month/year) 25 November 1996 (25.11.96)
Applicant OHKI, Hidenori et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:

20 May 1998 (20.05.98)

☐ in a notice effecting later election filed with the International Bureau on:2. The election ☒ was☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer K. Takeda Telephone No.: (41-22) 338.83.38
--	--

BEST AVAILABLE COPY

PATENT COOPERATION TREATY

PCT

From the INTERNATIONAL BUREAU

NOTIFICATION CONCERNING
SUBMISSION OF PRIORITY DOCUMENTS

(PCT Administrative Instructions, Section 411)

To:

SEKI, Hideo
Fujisawa Pharmaceutical Co., Ltd.
Osaka Factory
1-6, Kashima 2-chome
Yodogawa-ku, Osaka-shi
Osaka 532
JAPON

Date of mailing (day/month/year) 03 December 1997 (03.12.97)		
Applicant's or agent's file reference PWO-16397		
IMPORTANT NOTIFICATION		
International application No. PCT/JP97/04193	International filing date (day/month/year) 18 November 1997 (18.11.97)	Priority date (day/month/year) 25 November 1996 (25.11.96)
Applicant FUJISAWA PHARMACEUTICAL CO., LTD. et al		

The applicant is hereby notified of the date of receipt by the International Bureau of the priority document(s) relating to the following application(s):

<u>Priority application No:</u>	<u>Priority date:</u>	<u>Priority country:</u>	<u>Date of receipt of priority document:</u>
PO3814	25 Nov 1996 (25.11.96)	AU	01 Dec 1997 (01.12.97)

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer K. Takeda Telephone No.: (41-22) 338.83.38
---	---

PCT

From the INTERNATIONAL BUREAU

**NOTICE INFORMING THE APPLICANT OF THE
COMMUNICATION OF THE INTERNATIONAL
APPLICATION TO THE DESIGNATED OFFICES**

(PCT Rule 47.1(c), first sentence)

To:

SEKI, Hideo
Fujisawa Pharmaceutical Co., Ltd.
Osaka Factory
1-6, Kashima 2-chome
Yodogawa-ku, Osaka-shi
Osaka 532
JAPON

Date of mailing (day/month/year)

04 June 1998 (04.06.98)

Applicant's or agent's file reference

PWO-16397

IMPORTANT NOTICE

International application No.

PCT/JP97/04193

International filing date (day/month/year)

18 November 1997 (18.11.97)

Priority date (day/month/year)

25 November 1996 (25.11.96)

Applicant

FUJISAWA PHARMACEUTICAL CO., LTD. et al

1. Notice is hereby given that the International Bureau has communicated, as provided in Article 20, the international application to the following designated Offices on the date indicated above as the date of mailing of this Notice:
CA,CN,EP,JP,KR,US

In accordance with Rule 47.1(c), third sentence, those Offices will accept the present Notice as conclusive evidence that the communication of the international application has duly taken place on the date of mailing indicated above and no copy of the international application is required to be furnished by the applicant to the designated Office(s).

2. The following designated Offices have waived the requirement for such a communication at this time:
None

The communication will be made to those Offices only upon their request. Furthermore, those Offices do not require the applicant to furnish a copy of the international application (Rule 49.1(a-bis)).

3. Enclosed with this Notice is a copy of the international application as published by the International Bureau on
04 June 1998 (04.06.98) under No. WO 98/23637

REMINDER REGARDING CHAPTER II (Article 31(2)(a) and Rule 54.2)

If the applicant wishes to postpone entry into the national phase until 30 months (or later in some Offices) from the priority date, a **demand for international preliminary examination** must be filed with the competent International Preliminary Examining Authority before the expiration of 19 months from the priority date.

It is the applicant's sole responsibility to monitor the 19-month time limit.

Note that only an applicant who is a national or resident of a PCT Contracting State which is bound by Chapter II has the right to file a demand for international preliminary examination.

REMINDER REGARDING ENTRY INTO THE NATIONAL PHASE (Article 22 or 39(1))

If the applicant wishes to proceed with the international application in the **national phase**, he must, within 20 months or 30 months, or later in some Offices, perform the acts referred to therein before each designated or elected Office.

For further important information on the time limits and acts to be performed for entering the national phase, see the Annex to Form PCT/IB/301 (Notification of Receipt of Record Copy) and Volume II of the PCT Applicant's Guide.

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No. (41-22) 740.14.35

Form PCT/IB/308 (July 1996)

Authorized officer

J. Zahra

Telephone No. (41-22) 338.83.38

ENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference PWO-16397	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/JP 97/04193	International filing date (day/month/year) 18/11/1997	(Earliest) Priority Date (day/month/year) 25/11/1996
Applicant FUJISAWA PHARMACEUTICAL CO., LTD. et al.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 3 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. ☒ Certain claims were found unsearchable (see Box I).

2. ☐ Unity of invention is lacking (see Box II).

3. ☐ The international application contains disclosure of a nucleotide and/or amino acid sequence listing and the international search was carried out on the basis of the sequence listing

☐ filed with the international application.

☐ furnished by the applicant separately from the international application,

☐ but not accompanied by a statement to the effect that it did not include matter going beyond the disclosure in the international application as filed.

☐ Transcribed by this Authority

4. With regard to the title, ☐ the text is approved as submitted by the applicant.

☒ the text has been established by this Authority to read as follows:

CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY

5. With regard to the abstract,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this International Search Report, submit comments to this Authority.

6. The figure of the drawings to be published with the abstract is:

Figure No. ☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☐ None of the figures.

BEST AVAILABLE COPY

INTERNATIONAL SEARCH REPORT

International application No.
PCT/JP 97/04193

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons.

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 12 and 14 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/JP 97/04193

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07K7/56 A61K38/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 11210 A (FUJISAWA PHARMACEUTICAL CO ;OHKI HIDENORI (JP); TOMISHIMA MASAKI () 18 April 1996	1-14
Y	see the whole document	1,5,8, 10-14
Y	--- EP 0 561 639 A (LILLY CO ELI) 22 September 1993 see the whole document	1,5,8, 10-14
A	--- EP 0 644 199 A (FUJISAWA PHARMACEUTICAL CO) 22 March 1995 see the whole document	1-14
A	--- EP 0 486 011 A (FUJISAWA PHARMACEUTICAL CO) 20 May 1992 cited in the application see the whole document -----	1-14

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

18 February 1998

Date of mailing of the international search report

04.03.98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Groenendijk, M

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/JP 97/04193

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9611210 A	18-04-96	AU 3578095 A BR 9504791 A CA 2202058 A EP 0788511 A FI 971397 A NO 971544 A ZA 9508458 A	02-05-96 22-10-96 18-04-96 13-08-97 27-05-97 04-06-97 07-05-96
EP 0561639 A	22-09-93	AU 3534193 A AU 6552996 A BR 9301232 A CA 2091663 A CN 1080926 A CZ 9300416 A HU 9500378 A JP 6056892 A MX 9301457 A NZ 247149 A ZA 9301830 A	23-09-93 05-12-96 21-09-93 20-09-93 19-01-94 13-07-94 30-10-95 01-03-94 28-02-94 28-10-96 15-09-94
EP 0644199 A	22-03-95	AU 681119 B AU 6199494 A CA 2123921 A CN 1100104 A HU 68385 A JP 6340693 A US 5569646 A US 5693750 A ZA 9403356 A	21-08-97 24-11-94 18-11-94 15-03-95 28-06-95 13-12-94 29-10-96 02-12-97 28-03-95
EP 0486011 A	20-05-92	JP 5000966 A US H1638 H AT 143671 T AU 651347 B AU 7843591 A CA 2044746 A CN 1059729 A DE 69122432 D EP 0462531 A EP 0729974 A	08-01-93 04-03-97 15-10-96 21-07-94 16-01-92 19-12-91 25-03-92 07-11-96 27-12-91 04-09-96

INTERNATIONAL SEARCH REPORT


Information on patent family members

International Application No

PCT/JP 97/04193

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0486011 A		ES 2093658 T	01-01-97
		HU 9500349 A	28-09-95
		IL 98506 A	12-09-96
		JP 4352799 A	07-12-92
		OA 9369 A	15-09-92
		US 5376634 A	27-12-94

PATENT COOPERATION TREATY



PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)



Applicant's or agent's file reference PWO-16397	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (PCT/IPEA/416)	
International application No. PCT/JP97/04193	International filing date (day/month/year) 18/11/1997	Priority date (day/month/year) 25/11/1996
International Patent Classification (IPC) or national classification and IPC C07K7/56		
Applicant FUJISAWA PHARMACEUTICAL CO., LTD. et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 7 sheets, including this cover sheet.
- ☐ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☒ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand 20/05/1998	Date of completion of this report 21.01.99
Name and mailing address of the IPEA/  European Patent Office D-80298 Munich Tel. (+49-89) 2399-0, Tx: 523656 epmu d Fax: (+49-89) 2399-4465	Authorized officer Williere, G Telephone No. (+49-89) 2399-8548 

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/JP97/04193

I. Basis of the report

1. This report has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.*):

Description, pages:

1-100 as originally filed

Claims, No.:

1-14 as originally filed

2. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
☐ the claims, Nos.:
☐ the drawings, sheets:

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

IV. Lack of unity of invention

1. In response to the invitation to restrict or pay additional fees the applicant has:

- ☐ restricted the claims.
☐ paid additional fees.
☐ paid additional fees under protest.
☐ neither restricted nor paid additional fees.

2. ☒ This Authority found that the requirement of unity of invention is not complied and chose, according to Rule 68.1, not to invite the applicant to restrict or pay additional fees.

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/JP97/04193

3. This Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 is

☐ complied with.

☒ not complied with for the following reasons:

see separate sheet

4. Consequently, the following parts of the international application were the subject of international preliminary examination in establishing this report:

☒ all parts.

☐ the parts relating to claims Nos. .

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims 4,7,9
	No:	Claims 1-3,5,6,8,10-14
Inventive step (IS)	Yes:	Claims
	No:	Claims 1-14
Industrial applicability (IA)	Yes:	Claims 1-14
	No:	Claims

2. Citations and explanations

see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

see separate sheet

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/JP97/04193

Re Item IV

Lack of unity of invention

1. Unity of invention is fulfilled only when there is a technical relationship among those inventions involving one or more of the same or corresponding special technical features. **The expression 'special technical features' shall mean those technical features** which define a contribution which each of the claimed invention considered as a whole makes over the prior art."

Unity of invention for "Markush grouping" (present form of the claims) can only be acknowledged where

- i) all alternatives have a common property or activity, and
- ii) a significant (common) structural element.

Such a "significant structural element" must either be a large portion of the overall structure, or a distinctive (=inventive) portion in view of the prior art.

If it can be shown that at least one Markush alternative is not novel, and if the common matter of the independent claim(s) is well known, and the remaining subject-matter differs without there being any unifying novel concept common to all of them, then clearly there is lack of unity.

2. The presently claimed subject-matter does not fulfil the above requirements on unity of invention:

- i) In view of the closest prior art (D1 and D2; see item V below) and the description, the problem underlying the present application is the following:
"Provision of additional compounds having **antimicrobial** activity and the characteristic structural feature of formula 1":

- ii) The solution to this problem in its broadest form is represented by the general formula 1.

- iii) A vague general formula as such is not regarded as the unifying concept. A novel and non-obvious "special technical feature" which would be regarded as the unifying concept (either a common property or activity, or a **significant structural element**; see above) must be common to all embodiments falling under that formula.

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/JP97/04193

iv) Compounds having the characteristic constant structural feature of the present application, together with the required activity, are known from D1, D2 and D3 (see item V below).

v) In the light of the above it is clear that there is no "special technical feature" which could serve as single inventive concept underlying the present application (Rule 13.1. PCT).

Re Item V

Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Reference is made to the following documents:

D1= WO 96 11210 A (FUJISAWA PHARMACEUTICAL CO ;OHKI HIDENORI (JP); TOMISHIMA MASAKI () 18 April 1996

D2= EP 0 561 639 A (LILLY CO ELI) 22 September 1993

D3= EP 0 644 199 A (FUJISAWA PHARMACEUTICAL CO) 22 March 1995

2.1. D1 discloses compounds 2,23,25,36,39-41,52,53,64-67,70-73,88,90,94-99, 101,102 and 124 (see pages 168-185). These compounds are disclosed as sodium salt of the corresponding sulfonic acid (see R²) and fall within the wording of present claims 1, 2, 5, 6 and 8. The subject-matter of said claims is in consequence not novel (Article 33(2) PCT).

Moreover the method for the preparation of the present compounds (see claim 10) is already known from D1 (see page 6). The subject-matter of claim 10 is thus not novel (Article 33(2) PCT).

2.2. D3 discloses compounds 11 (lignes 30 to 50), 12 (lignes 30 to 50), 5 (lignes 5 to 25), 6 (lignes 5 to 25) and 12 (lignes 5 to 25) falling within the wording of present claims 1 and 5. The subject-matter of said claims is in consequence not novel (Article 33(2) PCT).

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/JP97/04193

- 2.3. The presently claimed compounds (see claims 1 to 3, 11 and 13) and the subject-matter as claimed in D1, D2 and D3 (see claim 1) overlap to a certain extent. This overlap is novelty-destroying as there is apparently no new technical teaching (or new technical element) in the application in the range of overlap over the disclosure in the prior art. Having regard to the teaching of D1 (see D1 in its entirety), the skilled person would seriously contemplate working within the overlapping area as D1 clearly demonstrates that R¹ may be selected from a huge list a different moieties without altering the activity of the resulting compounds.
- 2.4. Novelty within an overlapping area, based on a selection, can only be recognised if it adds a novel element to the state of the art, thus containing another teaching of a technical way of doing things. In other words, novelty based on selection can only be acknowledged, if the scope of the claimed subject-matter is narrow, if it is sufficiently far removed from the preferred range of the citation, and if the effect associated with this selection confirms that there is not simply an arbitrary choice (i.e. better purity, improved yield, advantageous biological activity etc.)

None of these conditions is fulfilled in the present application. Consequently, the complete overlapping subject-matter has to be removed from the scope of the present application (Article 33(2) PCT).

3. The Applicant is furthermore informed that the presently claimed compounds (see claims 1 and 5) and the subject-matter as claimed in D2 (see claim 1, formula 1, wherein R₂ is represented by the formula at page 3, lines 20 to 25, Z is -O- or a carbon to carbon bond, R₄ is C₁ to C₁₂ alkoxy, C₂-C₁₂ alkynyl, phenyl substituted by C₁-C₁₂ alkoxy) overlap. Novelty for said claim 1 and 5 is therefore not present (please refer to paragraph 2.3.) (Article 33(2) PCT).
4. The subject-matter of present claims 1, 5, 12 and 14 is not novel (Article 33(2) PCT) as the compounds disclosed at page 8, table 2, line 20 and line 25 of D2 fall within the wording of said claims.
5. The subject-matter of present claims 4, 7 and 9 relates to compounds according to claim 1, wherein R¹ represents specific moieties which do not seem to be disclosed in the prior art documents as cited in the international search report.

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/JP97/04193

The subject-matter of claim 10 is directed to a method for the preparation of the compounds according to claim 1 not being disclosed in said prior art documents.

6. The Applicant is informed that whenever novelty is established for the compound claims, the presence of an inventive step has to be demonstrated. New compounds could only be considered to involve an inventive step in case they show an unexpected and advantageous effect when compared to the compounds of D1, D2 and D3 as these compounds merely differ from what might then be claimed by the R² position.

Re Item VIII

Certain observations on the international application

1. The use of the wordings "a substituent X substituted with substituent Y which has a substituent Z" or "a substituent X substituted with substituent Y which has a substituent Z having XY" is not clear. This wording is used throughout the application and should be corrected (Article 6 PCT).
2. The use of the relative and vague expressions "lower", "higher" and "one or more suitable substituents" in the claims (e.g. cyclo(**lower**)alkoxy, aryl having **higher** alkoxy) renders the scope of these claims unclear [Article 6 PCT, PCT Preliminary Examination Guidelines, chapter C-III, paragraphs 4.2 and 4.5, Rule 6.2 (a)].

These expressions should be clarified in the light of the description, page 9, lines 23 to 28.

The chemical structure shows a complex molecule with multiple hydroxyl groups, amide bonds, and a central amine group labeled NH-R¹. The structure includes a benzene ring with a hydroxyl group and a substituent R², and a methyl group (H₃C).

(1)

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		